Pneumococcal conjugate second or third-dose vaccines (PCVc) in Rwanda
Rwanda: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 96.0% in 2025. ▲ Rising
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Rwanda, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
Rwanda recorded 96.0% for pneumococcal conjugate second or third-dose vaccines (pcvc) in 2025.
The figure is down 2.0% on the previous year and down 2.0% over ten years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Rwanda peaked at 98.0% in 2012 and was at its lowest, 0.0%, in 2008.
Rwanda ranks 27th of 194 countries on this measure, in the top quarter.
The long-run direction has been consistently rising across the 18 years of available data.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Rwanda, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 97.0% | — |
| 2011 | 97.0% | +0.0% |
| 2012 | 98.0% | +1.0% |
| 2013 | 98.0% | +0.0% |
| 2014 | 98.0% | +0.0% |
| 2015 | 98.0% | +0.0% |
| 2016 | 98.0% | +0.0% |
| 2017 | 98.0% | +0.0% |
| 2018 | 97.0% | -1.0% |
| 2019 | 98.0% | +1.0% |
| 2020 | 91.0% | -7.1% |
| 2021 | 88.0% | -3.3% |
| 2022 | 97.0% | +10.2% |
| 2023 | 94.0% | -3.1% |
| 2024 | 98.0% | +4.3% |
| 2025 | 96.0% | -2.0% |
Rwanda compared with similar countries
- Rwanda's 96.0% is above the median for low income countries, which is 80.0%, 1.2× the median. (25 countries reporting)
- Rwanda's 96.0% is above the median for Sub-Saharan Africa, which is 82.5%, 1.2× the median. (48 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 97.7% | 97.0% | 98.0% | 10 |
| 2020s | 94.0% | 88.0% | 98.0% | 6 |
Countries ranked near Rwanda
More health data for Rwanda
- Un projection of annual infant deaths, annual growth rate -1.08 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.891 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 860.6 deaths per 1,000 people (2090)
- Number of infants who die before age 1 2,738 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 1 (2025)
- Population ages 00-04, female, annual growth rate 0.9441 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0.0001 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.065 units per person (2025)
- Population ages 00-04, male, annual growth rate 0.9697 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0.0001 units per US$ of GDP (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Rwanda?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Rwanda was 96.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Rwanda?
- The highest recorded value was 98.0% in 2012.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Rwanda?
- The lowest recorded value was 0.0% in 2008.
- How does Rwanda rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Rwanda ranks 27th out of 194 countries with data for 2025.
- Is pneumococcal conjugate second or third-dose vaccines (pcvc) rising or falling in Rwanda?
- Over the last ten years it is down 2.0%. The long-run trend across the full record is rising.
- Where does this Rwanda data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).